Skip to main content

Biocept to Host Key Opinion Leader Webinar on October 14 to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System

Presenters include leading neuro-oncologists Dr. Priya U. Kumthekar of Northwestern University and Dr. Seema A. Nagpal of Stanford University

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces an hour-long webinar to be held October 14 at 1 p.m. Eastern time featuring case studies presented by leading neuro-oncologists who have used the company’s CNSide assay in the management of patients with confirmed or suspected central nervous system metastasis. The webinar will feature key opinion leaders Priya U. Kumthekar, MD of Northwestern University and Seema A. Nagpal, MD of Stanford University.

“We appreciate Drs. Kumthekar and Nagpal’s willingness to share their real-world clinical experience with CNSide, in managing patients with a time-sensitive, life-threatening complication of cancer,” said Michael Dugan, MD, Biocept’s Senior Vice President, Chief Medical Officer and Medical Director. “CNSide provides an enhanced method of cell capture with digital imaging for the quantitative evaluation of tumor cells recovered from cerebral spinal fluid (CSF). This provides a more accurate method of assessing the intracranial response to treatment than more subjective methods currently used to evaluate metastatic cancers involving the central nervous system. Additionally, CNSide can be used to identify biomarkers associated with tumor progression and metastasis to better inform physician treatment decisions and patient care plans, while providing tumor cell counts that can be used by them to more quickly assess both treatment response and disease progression or resistance to treatment.”

“Our goals are to position Biocept as the leader in the emerging category of neurological tumor diagnostics, and to become the provider of choice for biopharma companies seeking to develop therapies to treat cancer that has metastasized to the central nervous system,” said Sam Riccitelli, Biocept’s Chairman and interim CEO. “Our customer base has consistently grown since CNSide’s early access commercial launch in early 2020. More than 100 physicians including physicians from more than one-third of the elite 64 National Cancer Institute-designated cancer centers have used our product. We estimate the annual market opportunity for CNSide for our initial applications at $1.2 billion in the U.S. and $2 billion globally.”

Webinar Details

Date: Friday, October 14

Time: 1:00 p.m. Eastern time (10:00 a.m. Pacific time)

Registration: Participants can pre-register or register at webinar start time here

The webinar will be available live and archived at

About the Speakers

Priya U. Kumthekar, MD is a United Counsel for Neurologic Subspecialties (UCNS)-certified neuro-oncologist from Northwestern University and is serving as the principal investigator for Biocept’s FORESEE clinical study. She is dedicated to patient care and moving the study of brain tumors forward primarily through her leadership on clinical trials. Dr. Kumthekar serves in leadership roles with the National Clinical Trials Network, particularly with the Alliance for Clinical Trials, and was named as the Alliance’s national Executive Officer of Neuro-Oncology in 2016. In this role, she oversees the conception and development of clinical trials from early phase through registration studies. Dr. Kumthekar is board certified in neurology and is a member of the American Board of Psychiatry and Neurology. She received her medical degree from Northeastern Ohio University. She previously was Chief Resident at Northwestern University, McGaw Medical Center and has led numerous trials involving primary and secondary brain tumors.

Seema A. Nagpal, MD is a board-certified neuro-oncologist and has served as Clinical Associate Professor at Stanford University since 2012. She treats patients with primary brain tumors and metastatic disease to the brain and nervous system. Her research concentrates on clinical trials for patients with late-stage central nervous system cancer and she has a special interest in leptomeningeal disease, a devastating complication of lung and breast cancers. In collaboration with Stanford scientists, including breast and lung oncologists, Dr Nagpal’s work is focused on more sensitive disease detection and the improvement of patient outcomes. She previously was a neuro-oncology fellow at Stanford hospitals and clinics, and a neurology resident at the University of California San Francisco. She received her medical degree from the University of Pennsylvania.

About Biocept

Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide™ cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept’s patented Target Selector™ technology captures and quantitatively analyzes cerebrospinal fluid tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic. For more information, visit Follow Biocept on Facebook, LinkedIn and Twitter.

Forward-Looking Statements Disclaimer Statement

This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend" or "project," or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this news release are not strictly historical, including, without limitation, statements as to our ability to establish our CSF assay as the new standard of care for the diagnosis of patients with suspected cancer metastasis to the CNS under National Comprehensive Cancer Network guidelines and our ability to provide physicians with clinically actionable information to improve the outcomes of cancer patients, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this news release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC at


Investor and Media Contact

LHA Investor Relations

Jody Cain, (310) 691-7100

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.